PTPI
NASDAQPetros Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.06+0.00 (+0.00%)
2026-02-172026-05-20
News · 26 weeks13+400%
2025-12-072026-05-31
Mix790d
- SEC Filings3(43%)
- Insider3(43%)
- Other1(14%)
Latest news
25 items- INSIDEROfficer Boctor Fady was granted 375,000 shares, increasing direct ownership by 72% to 894,986 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- INSIDERDirector Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 99% to 3,762,334 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- INSIDERDirector Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 99% to 8,790,450 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECSEC Form 10-Q filed by Petros Pharmaceuticals Inc.10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECSEC Form 10-K filed by Petros Pharmaceuticals Inc.10-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECSEC Form NT 10-K filed by Petros Pharmaceuticals Inc.NT 10-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
- INSIDEROfficer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- INSIDERDirector Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- INSIDERDirector Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- INSIDERDirector Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 15,202% to 1,887,334 units (SEC Form 4)4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
- SECSEC Form 25-NSE filed by Petros Pharmaceuticals Inc.25-NSE - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
- SECSEC Form 10-Q filed by Petros Pharmaceuticals Inc.10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
- SECSEC Form 10-Q filed by Petros Pharmaceuticals Inc.10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- NEWSPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionNEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC ("Metuchen"), including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, LLC, from its consolidated balance sheet, effective beginning in its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025. This move is expected to significantly improve Petros' financial position, increasing stockholders' equity and m
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- NEWSPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsThe Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros' securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker "PTPI".
- SECPetros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
- NEWSPetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperWith more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces its partnership with Innolitics, a leading developer in the Software-as-a-Medical Device space. The collaboration is intended to integrate many of the Company's emerging capabilities in the ongoing development of its first-in-industry SaaS platform designed to complement its proprietary web
- SECSEC Form 10-Q filed by Petros Pharmaceuticals Inc.10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
PTPI FAQ
5 questionsWhat does Petros Pharmaceuticals Inc. do?
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.Where does PTPI stock trade?
Petros Pharmaceuticals Inc. (PTPI) is listed on NASDAQ.What sector and industry is PTPI in?
Petros Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to PTPI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PTPI side-by-side with any of them on Quantisnow.How can I track PTPI on Quantisnow?
Quantisnow aggregates Petros Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTPI to receive live email and push alerts on every new disclosure.